drugset / Trial / NCT03413384

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

NCT03413384

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University Hospital, Kaohsiung Chang Gung Memorial Hospital, China Medical University Hospital, Changhua Christian Hospital, and Taipei Veterans General Hospital.

Timeline

Start
2019-02-15
Primary completion
2025-07-28
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftriaxone Other / unclassified 1 g Intramuscular

Indications